• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

New ACC/AHA cholesterol guidelines emphasize the appropriate-level statin treatment

bys25qthea
January 28, 2014
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. New clinical guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA) recommend statin use in certain patient populations based on age, 10-year atherosclerotic cardiovascular disease (ASCVD) risk level, and blood LDL-C level.

2. The guidelines also suggest use of a new equation for estimating ASCVD risk in patients.

Evidence Rating Level: 1 (Excellent)

Study Rundown:  ASCVD is the leading cause of death in Americans, and its treatment costs the US healthcare system billions of dollars annually. The ACC/AHA released updated clinical guidelines for the screening and management of ASCVD. These guidelines emphasize an active, healthy lifestyle and diet as the primary methods for preventing ASCVD in all patients. In addition, the guidelines also advocate the use of statins as primary prevention in patients with: (1) clinical ASCVD, (2) LDL levels of 190 mg/dL or higher, (3) aged 40 to 75 years with diabetes and LDL levels of 70 to 189 mg/d and, (4) those aged 40 to 75 years without diabetes and with a ten-year ASCVD risk of 7.5% or higher.

Importantly, the new guidelines do not show enough evidence to support treatment to LDL or non-HDL cholesterol goals in patients. Rather, at-risk patients should be maintained on proper statin therapy for as long as they can tolerate the drug without serious side effects (e.g. myopathy). The last major recommendation states that the Pooled Cohort Equations are the best option for estimating ten-year ASCVD risk as a precursor to statin initiation.

These new guidelines have sparked some controversy.  In particular, the abandonment of the LDL and non-HDL targets for statin treatments has been criticized.  While using these cholesterol levels as the sole determinant of statin therapy initiation/maintenance is widely regarded as ill-advised, these lipid measurements can still serve as valuable metrics of treatment efficacy during follow-up visits. Also, the new risk calculation method has not been released free of concerns, since it has been reported to overestimate the risk for ASCVD by 70% to 150%. The many factors comprising the algorithms behind the risk equations should be reviewed in conjunction with randomized, controlled trials and adjusted as necessary to refine the equations’ predictive value.

RELATED REPORTS

#VisualAbstract: Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs

In-Depth [systematic review]: The National Heart, Lung and Blood Institute (NHLBI) convened the Adult Treatment Panel IV (ATP-IV) in 2008 in order to update cholesterol guidelines set forth in 2001 by the ATP-III. This was done by reviewing multiple randomized, controlled trials (RCTs) and meta-analyses of RCTs that studied cardiovascular outcomes. The reviews sought to answer questions about the evidence behind LDL and non-HDL levels as targets of treatment and about ASCVD event reduction versus adverse event occurrence for each cholesterol-lowering drug class. The strength of the evidence presented in each article reviewed was rated and resulting recommendations were graded according to criteria established by both the NHLBI and the ACC/AHA. The risk assessment equations used in the new risk calculator were conceived using data from five representative cohorts of African American and non-Hispanic white men and women. In September 2013, the ATP-IV’s recommendations were passed along to the ACC/AHA, where they were reviewed again before approval was given by both of these agencies.

By Nick Woolf and Aimee Li, MD

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: cholesterolstatin
Previous Post

2 Minute Medicine Rewind Jan 20 – Jan 26, 2014

Next Post

High mortality rates reported in ill patients with MERS-CoV

RelatedReports

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation
StudyGraphics

#VisualAbstract: Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation

December 8, 2022
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
Next Post
High mortality rates reported in ill patients with MERS-CoV

High mortality rates reported in ill patients with MERS-CoV

Ultrasound screening for AAAs has no effect on all-cause mortality

Ultrasound screening for AAAs has no effect on all-cause mortality

The PLCO trial 2: Flexible sigmoidoscopy in colon cancer screening [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options